This antibody is useful for Western Blot. Use in Immunohistochemistry-Paraffin reported in scientific literature (PMID 24635849). Use in In vitro, Immunohistochemistry-Frozen and blocking/neutralizing reported in scientific literature (PMID 26154387) The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Theoretical MW
59.9 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Reviewed Applications
Read 1 Review rated 5 using NB100-93579 in the following applications:
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Buffer
PBS
Preservative
0.02% Sodium Azide
Concentration
1 mg/ml
Purity
Immunogen affinity purified
Alternate Names for HERV Antibody
endogenous retroviral family W, env(C7), member 1
ENV
envelope glycoprotein
Envelope polyprotein gPr73
enverin
ENVW
Env-W
HERV-7q Envelope protein
HERV7Q
HERV-7q
HERV-tryptophan envelope protein
HERV-W Env glycoprotein
HERV-W envelope protein
HERV-W
HERV-W_7q21.2 provirus ancestral Env polyprotein
HERV-W{7q21.1} provirus ancestral Env polyprotein
HERVWENV
HERV-W-ENV
HERVWenvelope protein
human endogenous retrovirus W envC7-1 envelope protein
syncytin A
Syncytin
syncytin-1
Background
HERVs are a class of multiple sclerosis associated retroviruses. Reacts with a replication competent Human Endogenous Retrovirus (HERVW) isolated from placenta. The synthetic peptide sequence used as immunogen is taken from the virus envelope polyprotein sequence. Retroviral envelope proteins mediate receptor recognition and membrane fusion during early infection. Endogenous envelope proteins may have kept, lost or modified their original function during evolution. The HERVW endogenous envelope protein has retained its original fusogenic properties and participates in trophoblast fusion during placenta morphogenesis.
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
FAQs for HERV Antibody (NB100-93579). (Showing 1 - 1 of 1 FAQs).
Does the antibody recognize the HERV-W HYPER product, the digest result of the fool GENE PRODUCT HERV-W?
HERV Antibody [NB100-93579] is generated against immunogen sequence QRPGNIDAPC which shares sequence homology with your mentioned sequence which was..... FTLTAPPPCRCMTSSSPYQEFLWRMQRPGNIDAPSY...... Therefore, we strongly believe that our antibody NB100-93579 will be cross-reacting with your mentioned partial protein.
Bioinformatics Tool for HERV Antibody (NB100-93579)
Discover related pathways, diseases and genes to HERV Antibody (NB100-93579). Need help?
Read the Bioinformatics Tool Guide for instructions on using this tool.
Diseases for HERV Antibody (NB100-93579)
Discover more about diseases related to HERV Antibody (NB100-93579).
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.